Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms
AbstractHepatitis C virus (HCV) causes a major health burden and can be effectively treated by direct-acting antivirals (DAAs). The non-structural protein 5A (NS5A), which plays a role in the viral genome replication, is one of the DAAs’ targets. Resistance-associated viruses (RAVs) harbouring NS5A resistance-associated mutations (RAMs) have been described at baseline and after therapy failure. A mutation from glutamine to arginine at position 30 (Q30R) is a characteristic RAM for the HCV sub/genotype (GT) 1a, but arginine corresponds to the wild type in the GT-1b; still, GT-1b strains are susceptible to NS5A-inhibitors. In this study, we show that GT-1b strains with R30Q often display other specific NS5A substitutions, particularly in positions 24 and 34. We demonstrate that in GT-1b secondary substitutions usually happen after initial R30Q development in the phylogeny, and that the chemical properties of the corresponding amino acids serve to restore the positive charge in this region, acting as compensatory mutations. These findings may have implications for RAVs treatment. View Full-Text
- Supplementary File 1:
ZIP-Document (ZIP, 1354 KB)
Share & Cite This Article
Knops, E.; Sierra, S.; Kalaghatgi, P.; Heger, E.; Kaiser, R.; Kalinina, O.V. Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms. Genes 2018, 9, 343.
Knops E, Sierra S, Kalaghatgi P, Heger E, Kaiser R, Kalinina OV. Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms. Genes. 2018; 9(7):343.Chicago/Turabian Style
Knops, Elena; Sierra, Saleta; Kalaghatgi, Prabhav; Heger, Eva; Kaiser, Rolf; Kalinina, Olga V. 2018. "Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms." Genes 9, no. 7: 343.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.